We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-9.98%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$6.17B
AUM Growth
-$1.61B
Cap. Flow
-$473M
Cap. Flow %
-7.66%
Top 10 Hldgs %
32.27%
Holding
171
New
12
Increased
33
Reduced
25
Closed
28

Top Buys

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$89.7M
2
PFE icon
Pfizer
PFE
+$66.9M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$65.8M
4
ARGX icon
argenx
ARGX
+$49.4M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$47.1M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$136M
2
BMY icon
Bristol-Myers Squibb
BMY
+$116M
3
HCA icon
HCA Healthcare
HCA
+$100M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$82.9M
5
SVA
Sinovac Biotech, Ltd
SVA
+$72.7M

Sector Composition

Rank Sector Weight
1 Healthcare 97.72%
2 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XFOR icon
126
X4 Pharmaceuticals
XFOR
$377M
$2.4M 0.04%
45,795
– –
SGHT icon
127
Sight Sciences
SGHT
$291M
$2.31M 0.04%
200,000
– –
NBP
128
NovaBridge Biosciences American Depositary Shares
NBP
$186M
$1.8M 0.03%
111,120
– –
EXAI
129
DELISTED
Exscientia Plc American Depositary Shares
EXAI
$1.8M 0.03%
125,000
– –
ASLN
130
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$1.75M 0.03%
48,530
-720
-1% -$26.8K
GBT
131
CALL
DELISTED
Global Blood Therapeutics, Inc.
GBT
$1.73M 0.03%
+50,000
New +$1.49M
APTX
132
DELISTED
Aptinyx Inc. Common Stock
APTX
$1.22M 0.02%
538,500
-211,000
-28% -$632K
CABA icon
133
Cabaletta Bio
CABA
$427M
$1.17M 0.02%
577,509
+275,000
+91% +$719K
REUN
134
DELISTED
Reunion Neuroscience Inc. Common Shares
REUN
$762K 0.01%
115,386
-192,308
-62% -$1.6M
LBPH
135
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$606K 0.01%
113,500
– –
MIRM icon
136
Mirum Pharmaceuticals
MIRM
$6.56B
$595K 0.01%
+27,000
New +$551K
PYXS icon
137
Pyxis Oncology
PYXS
$185M
$580K 0.01%
143,640
– –
LABP
138
DELISTED
Landos Biopharma, Inc. Common Stock
LABP
$418K 0.01%
28,322
– –
OWLT.WS
139
DELISTED
Owlet, Inc. Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50
OWLT.WS
$170K ﹤0.01%
220,704
– –
ADAG
140
Adagene
ADAG
$246M
– –
-263,176
Closed -$2.12M
APLT
141
DELISTED
Applied Therapeutics
APLT
– –
-2,313,681
Closed -$20.7M
CRIS icon
142
Curis
CRIS
$9.71M
– –
-9,087
Closed -$17.3M
CTKB icon
143
Cytek Biosciences
CTKB
$566M
– –
-1,923,139
Closed -$31.4M
CVRX icon
144
CVRx
CVRX
$131M
– –
-723,055
Closed -$8.84M
DRUG
145
Bright Minds Biosciences
DRUG
$697M
– –
-132,120
Closed -$2.13M
GOSS icon
146
Gossamer Bio
GOSS
$101M
– –
-683,000
Closed -$7.72M
GYRE icon
147
Gyre Therapeutics
GYRE
$629M
– –
-230,587
Closed -$1.58M
HCA icon
148
HCA Healthcare
HCA
$90.6B
– –
-389,500
Closed -$100M
IFRX icon
149
InflaRx
IFRX
$243M
– –
-875,297
Closed -$4.17M
INZY
150
DELISTED
Inozyme Pharma
INZY
– –
-526,600
Closed -$3.59M
3 4 5
6
7

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q1 2022 Portfolio in Review

As of Q1 2022, OrbiMed held 171 positions worth $6.17B, down 21% from $7.78B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

OrbiMed withdrew a net $473M in Q1 2022, closing 28 positions and reducing 25 holdings. Its most notable exit was Merck, an estimated $136M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 96% a quarter earlier, followed by Industrials.

Against the trend, OrbiMed opened a new position in Biohaven Pharmaceutical Holding Company Ltd. worth $85.3M.

  • OrbiMed's largest Q1 2022 buy was Biohaven Pharmaceutical Holding Company Ltd.: 719,034 shares worth $85.3M.
  • OrbiMed added most to Pfizer in Q1 2022, an estimated $66.9M increase.
  • OrbiMed's biggest Q1 2022 reduction was Bristol-Myers Squibb, cutting an estimated $116M.
  • OrbiMed fully exited Merck in Q1 2022, selling an estimated $136M.
  • OrbiMed's ten largest holdings make up 32% of its $6.17B portfolio in Q1 2022.
  • OrbiMed opened 12 new positions and closed 28 in Q1 2022.
  • OrbiMed's portfolio value fell 21% quarter-over-quarter to $6.17B.

Based on OrbiMed's 13F filing for Q1 2022, filed 16 May 2022.